Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net earnings	$ 257,781	$ 165,709
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	70,536	37,533
Amortization of deferred loan costs	6,238	15,645
Provision for uncollectibles	212,546	69,715
Net loss on sale of long-lived assets	0	2,468
Net gain on deconsolidations	(5,854)	(3,411)
Share-based compensation	11,319	7,388
Excess tax benefit from share-based compensation	(3,779)	(2,288)
Deferred income taxes	7,309	31,388
Equity in earnings of unconsolidated affiliates	(11,575)	(3,461)
Debt extinguishment costs	0	4,536
Net change in fair value of contingent consideration	8,338	0
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	(232,465)	(65,758)
Supplies inventory	(533)	68
Prepaid and other current assets	36,479	(24,414)
Accounts payable	2,316	(10,007)
Accrued expenses and other liabilities	64,760	48,368
Other, net	3,786	2,572
Net cash flows provided by operating activities	427,202	276,051
Cash flows from investing activities:
Acquisitions and related expenses	(233,490)	(2,138,648)
Acquisition of property and equipment	(47,006)	(23,109)
Proceeds from sale of interests in surgery centers	0	4,969
Purchases of marketable securities	(1,743)	(3,486)
Maturities of marketable securities	4,233	0
Other	(3,974)	2,082
Net cash flows used in investing activities	(281,980)	(2,158,192)
Cash flows from financing activities:
Proceeds from long-term borrowings	10,197	2,046,399
Repayment on long-term borrowings	(15,737)	(403,043)
Distributions to noncontrolling interests	(158,144)	(139,443)
Proceeds from preferred stock offering	0	172,500
Cash dividends for preferred shares	(6,792)	(2,239)
Proceeds from common stock offering	0	439,875
Proceeds from issuance of common stock upon exercise of stock options	2,356	2,150
Repurchase of common stock	(3,684)	(2,890)
Excess tax benefit from share-based compensation	3,779	2,288
Payments of equity issuance costs	0	(24,366)
Financing cost incurred	(294)	(65,673)
Other	2,440	(176)
Net cash flows provided by (used in) financing activities	(165,879)	2,025,382
Net increase (decrease) in cash and cash equivalents	(20,657)	143,241
Cash and cash equivalents, beginning of period	208,079	50,840
Cash and cash equivalents, end of period	187,422	194,081
Supplemental cash flow information:
Interest payments	96,418	20,440
Income tax paid, net of refunds	$ 28,429	$ 6,970